Industry clinical trials in are a vital engine of medical innovation and economic growth, with the European Economic Area (EEA) generating €35.7 billion in Gross Value Added (GVA) in 2025 from these activities. This includes €21.7 billion from direct, indirect, and induced effects, €3.6 billion f...

Merck's portfolio optimization strategy includes reorganizing its Human Health division into two focused business units—Oncology and Specialty, Pharma & Infectious Diseases—to sharpen commercial execution across its growing pipeline. This

A recently published systematic literature review synthesizes evidence from 50 publications across 43 studies on the economic burden NSCLC in locally advanced (stage IIIB/C) and metastatic (stage IV) non-small cell lung cancer, highlighting high healthcare resource utilization (HCRU) rates includ...

AI Literature Review Integration is transforming systematic literature reviews (SLRs), as outlined in this preprint. It provides methodological guidance for incorporating artificial intelligence (AI) into SLRs with a human-in-the-loop approa...

Court Clerical Error Threatens Infarmed Vaccine Data Transparency Infarmed vaccine data transparency hangs in the balance due to a clerical error by the Lisbon Administrative Court's secretariat, which sent a January...

The EMA Executive Director Recruitment procedure has opened, a pivotal role overseeing operations like medicine authorizations, safety monitoring, and EU-wide public health responses. This vacancy, with reference COM/2026/20118, reports to the EMA Management Board, managing a 2025 budget of about...